Comparison
Bromantane vs Urolithin A
Side-by-side of Bromantane and Urolithin A. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
Urolithin A
Urolithin A supplement guide: pomegranate-derived metabolite, 500-1000 mg Mitopure dosing, mitophagy and muscle endurance evidence.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
Urolithin A
- •Gut-microbiome-derived metabolite of pomegranate and walnut ellagitannins
- •Roughly 40% of adults are 'urolithin producers' from dietary intake; ~60% are non-producers
- •Ryu 2016 (Nature Medicine) reported lifespan extension in C. elegans and muscle benefits in aged rodents
- •Andreux 2019 first-in-human trial (n=60) established safety and mitochondrial gene-expression upregulation
- •Singh 2022 (n=66, 4 months, 1000 mg/day) reported improved muscle endurance in older adults
- •Most human trial portfolio is Amazentis-funded; independent replication is thin
Side-by-side
| Attribute | Bromantane | Urolithin A |
|---|---|---|
| Category | nootropic | supplement |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | UA, Mitopure, ellagitannin metabolite |
| Half-life (hr) ↗ | 11 | 17 |
| Typical dose (mg) ↗ | 75 | 500 |
| Dosing frequency | daily, morning | daily, morning with food |
| Routes | oral | oral |
| Onset (hr) | 3 | 2 |
| Peak (hr) | 168 | 4 |
| Molecular weight | 280.21 | 228.2 |
| Molecular formula | C16H20BrN | C13H8O4 |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Induces mitophagy via potentiation of PINK1/Parkin signaling, leading to selective degradation of damaged mitochondria. Secondary anti-inflammatory effects via NF-kB modulation. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | OTC dietary supplement (US GRAS 2018; EFSA Novel Food 2021) |
| WADA status | banned | allowed |
| DEA / Rx | Not scheduled in the US | OTC supplement (not scheduled) |
| Pregnancy | Not recommended | Insufficient data; not routinely recommended |
| CAS | 87913-26-6 | 1143-70-0 |
| PubChem CID | 9576456 | 5488186 |
| Wikidata | Q4093816 | Q27101321 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
Urolithin A
Common side effects
- mild GI upset (rare)
- soft stools (rare)
Contraindications
- pregnancy and lactation (insufficient data)
- active chemotherapy (consult oncology)
Interactions
- chemotherapy agents: theoretical interaction with mitochondrial-targeting agents; consult oncologist(moderate)
Which Should You Take?
Urolithin A comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Bromantane is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Bromantane.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is healthspan extension, pick Urolithin A.
- → If your priority is muscle hypertrophy, pick Urolithin A.
Edge case: If you want to avoid controlled substance, Urolithin A is the more accessible choice.
Default choice: Urolithin A. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Bromantane only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and Urolithin A?
Bromantane and Urolithin A differ in category (nootropic vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or Urolithin A?
Bromantane half-life is 11 hours; Urolithin A half-life is 17 hours.
Can you stack Bromantane with Urolithin A?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper